Compare Bank of Montreal (BMO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Montreal vs TG Therapeutics Inc — how do they compare? Bank of Montreal trades at $181.45 (market cap $126.83B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Bank of Montreal is far larger — about 16.6× TG Therapeutics Inc's market cap, and Bank of Montreal pays a 2.69% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| BMO | TGTX | |
|---|---|---|
Market Cap | $126.83B | $7.64B |
Sector | Financials | Health |
52-Week High | $183.65 | $59.06 |
52-Week Low | $112.54 | $26.94 |
Dividend Yield | 2.69% | — |
Enterprise Value | — | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BMO stock trades at $183.60, up 0.93% today, with a bullish technical signal and consistent earnings beats. The company shows strong profitability with a 25.92% net income margin and a P/E of 19.41. Recent news includes the sale of Moneris for $1.44 billion and new ETN launches, highlighting strategic initiatives.
Outlook is positive due to earnings momentum and dividend stability, but risks include high debt levels and interest rate sensitivity. Analysts are divided with a 'Hold' consensus, suggesting cautious optimism amid macroeconomic uncertainties.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
